Stoke Therapeutics 향후 성장
Future 기준 점검 2/6
Stoke Therapeutics (는) 각각 연간 44.7% 및 56.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 45.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -28.4% 로 예상됩니다.
핵심 정보
44.7%
이익 성장률
45.22%
EPS 성장률
| Biotechs 이익 성장 | 25.2% |
| 매출 성장률 | 56.3% |
| 향후 자기자본이익률 | -28.45% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 11 May 2026 |
최근 향후 성장 업데이트
Recent updates
분석 기사 • May 11
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...
새로운 내러티브 • May 11
Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects
Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • May 01
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Summary I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen. STOK's $390.9M cash position, Biogen partnership, and low burn rate provide runway into mid-2028, mitigating near-term financing risk. Read the full article on Seeking Alpha분석 기사 • Jan 12
Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...분석 기사 • Dec 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...분석 기사 • Oct 09
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...분석 기사 • Aug 25
Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...분석 기사 • Aug 15
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...분석 기사 • May 20
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...분석 기사 • Apr 16
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...분석 기사 • Apr 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...분석 기사 • Feb 26
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Feb 16
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking Alpha분석 기사 • Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...분석 기사 • Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 07
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Summary STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. Despite recent stock gains, I may consider investing when Phase 3 trial enrollment is announced, given the promising genetic approach to Dravet Syndrome. Read the full article on Seeking Alpha분석 기사 • Jul 22
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jun 14
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Summary Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a Phase 1/2 candidate for Dravet syndrome, shows promising clinical results with seizure reduction and cognitive improvements. Collaborations with ACAD involve significant milestones and potential royalty payments, enhancing its financial outlook. STOK's financials are strong, with a healthy cash runway and potential for significant royalty revenues, making it a promising investment. Read the full article on Seeking Alpha이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 124 | -146 | -50 | -102 | 8 |
| 12/31/2027 | 46 | -215 | -187 | -196 | 10 |
| 12/31/2026 | 26 | -210 | -206 | -194 | 11 |
| 3/31/2026 | 32 | -170 | -148 | -147 | N/A |
| 12/31/2025 | 184 | -7 | 45 | 46 | N/A |
| 9/30/2025 | 206 | 41 | 52 | 53 | N/A |
| 6/30/2025 | 200 | 52 | 61 | 62 | N/A |
| 3/31/2025 | 191 | 50 | 69 | 70 | N/A |
| 12/31/2024 | 37 | -89 | -87 | -87 | N/A |
| 9/30/2024 | 17 | -105 | -85 | -84 | N/A |
| 6/30/2024 | 15 | -104 | -81 | -80 | N/A |
| 3/31/2024 | 8 | -109 | -86 | -84 | N/A |
| 12/31/2023 | 9 | -105 | -83 | -81 | N/A |
| 9/30/2023 | 9 | -103 | -85 | -83 | N/A |
| 6/30/2023 | 9 | -105 | -91 | -88 | N/A |
| 3/31/2023 | 15 | -99 | -89 | -86 | N/A |
| 12/31/2022 | 12 | -101 | -36 | -32 | N/A |
| 9/30/2022 | 9 | -100 | -30 | -26 | N/A |
| 6/30/2022 | 6 | -96 | -20 | -18 | N/A |
| 3/31/2022 | 3 | -94 | -16 | -14 | N/A |
| 12/31/2021 | N/A | -86 | -68 | -67 | N/A |
| 9/30/2021 | N/A | -76 | -63 | -62 | N/A |
| 6/30/2021 | N/A | -67 | -59 | -58 | N/A |
| 3/31/2021 | N/A | -58 | -52 | -52 | N/A |
| 12/31/2020 | N/A | -52 | -43 | -42 | N/A |
| 9/30/2020 | N/A | -48 | -43 | -41 | N/A |
| 6/30/2020 | N/A | -43 | -41 | -39 | N/A |
| 3/31/2020 | N/A | -38 | -37 | -35 | N/A |
| 12/31/2019 | N/A | -32 | N/A | -31 | N/A |
| 9/30/2019 | N/A | -26 | N/A | -24 | N/A |
| 6/30/2019 | N/A | -21 | N/A | -19 | N/A |
| 3/31/2019 | N/A | -16 | N/A | -16 | N/A |
| 12/31/2018 | N/A | -13 | N/A | -11 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: STOK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: STOK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: STOK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: STOK 의 수익(연간 56.3%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: STOK 의 수익(연간 56.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: STOK는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 20:55 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Stoke Therapeutics, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |